Results 181 to 190 of about 58,361 (283)

Mineralocorticoid receptor antagonists for acute myocardial infarction: a systematic review and meta-analysis of randomised controlled trials. [PDF]

Open Heart
Ang SP, Chia JE, Lima BB, Iglesias J, Lee E, Krittanawong C, Alam M, Mukherjee D.   +7 more
europepmc   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3974-3984, May 2026.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

The Effect of Glucocorticoid and Mineralocorticoid Receptor Antagonists in the Skin of Aged Female Mice. [PDF]

Int J Mol Sci
Ali A, Fossas De Mello N, Luo Y, Bensreti H, Melynk S, Shaver JC, Choudhary V, McGee-Lawrence ME, Bollag WB.   +8 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists promote renal immunosenescence. [PDF]

Int Urol Nephrol
Wang QR, Yang Y.
europepmc   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4314-4325, May 2026.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study. [PDF]

Eur Heart J Cardiovasc Pharmacother
Chen YH, Fang YW, Chen MT, Liou HH, Tsai MH.   +4 more
europepmc   +1 more source

Steroids:Modulators of inflammation and immunity [PDF]

, 2010
Chapman, Karen E, Odermatt, Alex
core   +1 more source

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4344-4351, May 2026.
ABSTRACT Aims Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population.
M. Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey, Peter Rossing   +4 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism.

J Clin Endocrinol Metab
Goi J, Paja Fano M, Rizo Gellida A, González-Boillos M, Martín Rojas-Marcos P, Caja Guayerbas L, García Cano AM, Ruiz-Sanchez JG, Vicente A, Gómez-Hoyos E, Recasens M, Barahona San Millan R, Picón César MJ, Díaz Guardiola P, Perdomo CM, Manjón-Miguélez L, Rebollo Román Á, Robles Lázaro C, Recio-Cordova JM, Calatayud M, Jiménez López N, Sampedro Nuñez M, Mena Ribas E, Sanmartín Sánchez A, Gonzalvo Diaz C, Lamas C, Serrano J, Michalopoulou T, Tenes Rodrigo S, Pascual-Corrales E, Jaén Aguila F, Muñoz Rivas N, Moya Mateo EM, Gutiérrez-Medina S, Hanzu FA, Parra Ramírez P, Araujo-Castro M.   +36 more
europepmc   +1 more source

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists. [PDF]

Rev Cardiovasc Med
Bozkurt B, Januzzi JL, Bansal S.
europepmc   +1 more source